Welcome to our dedicated page for Amylyx Pharmaceuticals SEC filings (Ticker: AMLX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) SEC filings page on Stock Titan provides access to the company’s official disclosures filed with the U.S. Securities and Exchange Commission. For a clinical-stage biopharmaceutical issuer focused on neurodegenerative and endocrine diseases, these documents are a primary source of information on financial condition, capital raising, and material program decisions.
Current reports on Form 8-K are especially relevant for AMLX. Recent 8-K filings have covered quarterly financial results, underwritten public offerings of common stock, and key R&D updates such as the decision to discontinue the ORION program of AMX0035 in progressive supranuclear palsy after Phase 2b results did not show differences versus placebo. Other 8-Ks describe the entry into underwriting agreements for equity offerings and the intended use of proceeds, including avexitide commercial readiness, research and development, working capital, and other general corporate purposes.
Investors can also use this page to track registration statements and prospectus supplements referenced in 8-Ks, which outline the terms of offerings and the securities being issued, as well as ongoing reporting obligations that detail research and development focus, cash runway expectations, and risk factors tied to Amylyx’ pipeline programs.
Stock Titan enhances these filings with AI-powered summaries that highlight the most important points from lengthy documents, helping users quickly understand items such as results of operations, material program changes, or capital structure updates. Real-time ingestion from the SEC’s EDGAR system means new Amylyx filings, including 8-Ks and other periodic reports, appear promptly, while structured views of exhibits and key sections make it easier to locate information on topics like avexitide development, AMX0035, AMX0114, and AMX0318.
For those analyzing AMLX stock, this page serves as a focused hub for reviewing the company’s regulatory record, understanding how it communicates material events, and seeing how financing activities align with its clinical-stage strategy.
Issuer files a Form 144 reporting the sale of common stock tied to vested restricted stock units and recent brokered transactions. The filing lists 22,522 shares associated with a 03/02/2026 vesting event and shows prior sales of 3,326 (01/06/2026) and 3,557 (02/02/2026) by James M. Frates.
The report names Morgan Stanley Smith Barney LLC as the broker and references NASDAQ as the market; timing and cash‑flow details are those shown on the reported trade dates.
AMLX reports a Form 144 disclosure covering recent transactions in its common stock. The issuer recorded the vesting of 20,545 restricted stock units on
AMLX lists insider resale activity by Joshua B. Cohen: a planned disposition of 57,529 common shares tied to vesting restricted stock units on
Amylyx Pharmaceuticals Chief Legal Officer Gina Mazzariello reported an automatic sale of company stock tied to tax withholding. On February 23, 2026, she sold 3,419 shares of common stock in open-market transactions at a weighted average price of $14.1422 per share. The filing explains these shares were sold automatically to cover tax obligations from the vesting of restricted stock units, not at her discretion. After these transactions, she beneficially owned 141,274 shares of Amylyx common stock.
AMLX reports a proposed sale of Common stock tied to the vesting of Restricted Stock Units, totaling 10,250 shares with an anticipated action date of
Amylyx Pharmaceuticals Inc. received an updated ownership filing showing that investment entities affiliated with TCG Crossover hold a significant passive stake in its common stock. TCG Crossover Fund II, L.P., together with its general partner TCG Crossover GP II, LLC and Chen Yu, report beneficial ownership of 6,243,812 shares.
This position represents 5.7% of Amylyx’s outstanding common stock, based on 109,819,659 shares outstanding as of October 27, 2025. The reporting parties state they share voting and dispositive power over these shares and certify the holdings are not for the purpose of changing or influencing control of the company.
Adage Capital Management, L.P. and related individuals report beneficial ownership of 2,777,055 shares of Amylyx Pharmaceuticals common stock, representing 2.53% of the outstanding shares. The shares are held with shared voting and dispositive power and reflect ownership of 5 percent or less of the class.
The filing is an amended Schedule 13G indicating a passive investment. The filers state the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Amylyx Pharmaceuticals.
FMR LLC has filed an amended Schedule 13G reporting a significant ownership stake in Amylyx Pharmaceuticals Inc. common stock. FMR and related entities beneficially own 16,468,419 shares, representing 15.0% of the outstanding common stock as of the event date.
The filing lists FMR with sole voting power over 16,417,957 shares and sole dispositive power over 16,468,419 shares. Abigail P. Johnson is reported with sole dispositive power over the same 16,468,419 shares. The securities are stated to be held in the ordinary course of business and not for the purpose of changing or influencing control of Amylyx.
Amylyx Pharmaceuticals, Inc. Chief Financial Officer James M. Frates reported an automatic sale of common stock tied to equity compensation taxes. On February 2, 2026, he sold 3,557 shares of Amylyx common stock at a weighted average price of $14.6463 per share to cover tax withholding from vesting restricted stock units. After this transaction, he directly held 173,547 shares, with additional shares held in several family trusts where he serves as trustee and disclaims beneficial ownership except for any pecuniary interest.
Amylyx Pharmaceuticals Co-Chief Executive Officer Joshua B. Cohen reported an automatic sale of common stock to cover taxes. On February 2, 2026, he sold 15,500 shares of Amylyx common stock at a weighted average price of $14.6834 per share.
The footnotes explain that these shares were required to be sold to satisfy tax withholding obligations from vested restricted stock units and were not sold at his discretion. After this tax-related sale, Cohen beneficially owned 3,363,965 shares of Amylyx common stock in direct ownership.